4/A: Aspira Women's Health Interim CEO Sandra Milligan Reports Stock Transactions

Interim CEO Sandra Milligan reports the vesting of restricted stock units and subsequent tax withholding, resulting in an adjustment to her holdings of Aspira Women's Health Inc. stock.

Summary

• Sandra Milligan, Interim CEO of Aspira Women's Health Inc., reported transactions involving the company's stock.
• On December 31, 2024, 20,000 restricted stock units (RSUs) vested and were converted into common stock.
• Following the vesting, a portion of the shares (6,356) were withheld for tax purposes on January 8, 2025, at a price of $0.7 per share.
• This amendment corrects the number of shares held after the tax withholding related to the RSU vesting.
• After these transactions, Milligan directly owns 13,644 shares of Aspira Women's Health Inc. common stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting standard executive compensation practices. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning executive interests with shareholder value.
• Tax withholding upon vesting of RSUs is a standard practice.
• Similar filings are routinely made by executives at comparable healthcare companies such as Exact Sciences or Hologic.

Stakeholder Impact

• Shareholders are informed about changes in insider ownership.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Aspira Women's Health Inc., Sandra Milligan, Interim CEO, Stock Transactions, Restricted Stock Units, RSUs, Vesting, Tax Withholding, Form 4, Beneficial Ownership